Cargando…
The molecular heterogeneity of sporadic colorectal cancer with different tumor sites in Chinese patients
PURPOSE: To assess the biological variability of clinical meaningful molecular markers and their clinical correlations in Chinese patients with colorectal cancer (CRC). MATERIALS AND METHODS: In this prospective observational study, frequencies and clinico-pathological features of RAS and BRAFV600E...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5564750/ https://www.ncbi.nlm.nih.gov/pubmed/28416767 http://dx.doi.org/10.18632/oncotarget.16176 |
_version_ | 1783258294775709696 |
---|---|
author | Peng, Junjie Huang, Dan Poston, Graeme Ma, Xiaoji Wang, Renjie Sheng, Weiqi Zhou, Xiaoyan Zhu, Xiaoli Cai, Sanjun |
author_facet | Peng, Junjie Huang, Dan Poston, Graeme Ma, Xiaoji Wang, Renjie Sheng, Weiqi Zhou, Xiaoyan Zhu, Xiaoli Cai, Sanjun |
author_sort | Peng, Junjie |
collection | PubMed |
description | PURPOSE: To assess the biological variability of clinical meaningful molecular markers and their clinical correlations in Chinese patients with colorectal cancer (CRC). MATERIALS AND METHODS: In this prospective observational study, frequencies and clinico-pathological features of RAS and BRAFV600E mutations, deficiency of DNA mismatch repair (dMMR) were evaluated in patients with colorectal cancer staged I-IV. The molecular heterogeneity between right-sided and left-sided colorectal cancers was studied in our series by classifying patients with different mutations and dMMR status. RESULTS: Among 400 evaluable patients, mutations in KRAS exon 2, exon 3 or 4, NRAS and BRAFV600E were detected in 36%, 7.5%, 3.5% and 2.5%, respectively. RAS mutations were significantly higher in metastatic CRCs (56.4% vs. 43.1%, p=0.015) and right-sided CRCs (62.5% vs 41.7%, p=0.003). In 212 RAS wild-type patients, V600E mutation was higher in older patients (9.5% vs. 2.2%, p=0.017), women (9.2% vs. 2.2%, p=0.021) and right-sided CRCs (10.5% vs. 3.4%, p=0.06). dMMR was detected in 7.75% of all stages of CRCs, with the highest dMMR rate of 40% in stage II right-sided colon cancer. CONCLUSIONS: By assessing the mutations and clinical correlations of RAS and BRAF genes, and dMMR status, similar RAS mutation, dMMR frequency and lower BRAF mutation was observed in Chinese patients compared to western patients. A distinct molecular heterogeneity was found between patients with right-sided and left-sided CRCs. |
format | Online Article Text |
id | pubmed-5564750 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-55647502017-08-23 The molecular heterogeneity of sporadic colorectal cancer with different tumor sites in Chinese patients Peng, Junjie Huang, Dan Poston, Graeme Ma, Xiaoji Wang, Renjie Sheng, Weiqi Zhou, Xiaoyan Zhu, Xiaoli Cai, Sanjun Oncotarget Research Paper PURPOSE: To assess the biological variability of clinical meaningful molecular markers and their clinical correlations in Chinese patients with colorectal cancer (CRC). MATERIALS AND METHODS: In this prospective observational study, frequencies and clinico-pathological features of RAS and BRAFV600E mutations, deficiency of DNA mismatch repair (dMMR) were evaluated in patients with colorectal cancer staged I-IV. The molecular heterogeneity between right-sided and left-sided colorectal cancers was studied in our series by classifying patients with different mutations and dMMR status. RESULTS: Among 400 evaluable patients, mutations in KRAS exon 2, exon 3 or 4, NRAS and BRAFV600E were detected in 36%, 7.5%, 3.5% and 2.5%, respectively. RAS mutations were significantly higher in metastatic CRCs (56.4% vs. 43.1%, p=0.015) and right-sided CRCs (62.5% vs 41.7%, p=0.003). In 212 RAS wild-type patients, V600E mutation was higher in older patients (9.5% vs. 2.2%, p=0.017), women (9.2% vs. 2.2%, p=0.021) and right-sided CRCs (10.5% vs. 3.4%, p=0.06). dMMR was detected in 7.75% of all stages of CRCs, with the highest dMMR rate of 40% in stage II right-sided colon cancer. CONCLUSIONS: By assessing the mutations and clinical correlations of RAS and BRAF genes, and dMMR status, similar RAS mutation, dMMR frequency and lower BRAF mutation was observed in Chinese patients compared to western patients. A distinct molecular heterogeneity was found between patients with right-sided and left-sided CRCs. Impact Journals LLC 2017-03-14 /pmc/articles/PMC5564750/ /pubmed/28416767 http://dx.doi.org/10.18632/oncotarget.16176 Text en Copyright: © 2017 Peng et al. http://creativecommons.org/licenses/by/3.0/ This article is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) (CC-BY), which permits unrestricted use and redistribution provided that the original author and source are credited. |
spellingShingle | Research Paper Peng, Junjie Huang, Dan Poston, Graeme Ma, Xiaoji Wang, Renjie Sheng, Weiqi Zhou, Xiaoyan Zhu, Xiaoli Cai, Sanjun The molecular heterogeneity of sporadic colorectal cancer with different tumor sites in Chinese patients |
title | The molecular heterogeneity of sporadic colorectal cancer with different tumor sites in Chinese patients |
title_full | The molecular heterogeneity of sporadic colorectal cancer with different tumor sites in Chinese patients |
title_fullStr | The molecular heterogeneity of sporadic colorectal cancer with different tumor sites in Chinese patients |
title_full_unstemmed | The molecular heterogeneity of sporadic colorectal cancer with different tumor sites in Chinese patients |
title_short | The molecular heterogeneity of sporadic colorectal cancer with different tumor sites in Chinese patients |
title_sort | molecular heterogeneity of sporadic colorectal cancer with different tumor sites in chinese patients |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5564750/ https://www.ncbi.nlm.nih.gov/pubmed/28416767 http://dx.doi.org/10.18632/oncotarget.16176 |
work_keys_str_mv | AT pengjunjie themolecularheterogeneityofsporadiccolorectalcancerwithdifferenttumorsitesinchinesepatients AT huangdan themolecularheterogeneityofsporadiccolorectalcancerwithdifferenttumorsitesinchinesepatients AT postongraeme themolecularheterogeneityofsporadiccolorectalcancerwithdifferenttumorsitesinchinesepatients AT maxiaoji themolecularheterogeneityofsporadiccolorectalcancerwithdifferenttumorsitesinchinesepatients AT wangrenjie themolecularheterogeneityofsporadiccolorectalcancerwithdifferenttumorsitesinchinesepatients AT shengweiqi themolecularheterogeneityofsporadiccolorectalcancerwithdifferenttumorsitesinchinesepatients AT zhouxiaoyan themolecularheterogeneityofsporadiccolorectalcancerwithdifferenttumorsitesinchinesepatients AT zhuxiaoli themolecularheterogeneityofsporadiccolorectalcancerwithdifferenttumorsitesinchinesepatients AT caisanjun themolecularheterogeneityofsporadiccolorectalcancerwithdifferenttumorsitesinchinesepatients AT pengjunjie molecularheterogeneityofsporadiccolorectalcancerwithdifferenttumorsitesinchinesepatients AT huangdan molecularheterogeneityofsporadiccolorectalcancerwithdifferenttumorsitesinchinesepatients AT postongraeme molecularheterogeneityofsporadiccolorectalcancerwithdifferenttumorsitesinchinesepatients AT maxiaoji molecularheterogeneityofsporadiccolorectalcancerwithdifferenttumorsitesinchinesepatients AT wangrenjie molecularheterogeneityofsporadiccolorectalcancerwithdifferenttumorsitesinchinesepatients AT shengweiqi molecularheterogeneityofsporadiccolorectalcancerwithdifferenttumorsitesinchinesepatients AT zhouxiaoyan molecularheterogeneityofsporadiccolorectalcancerwithdifferenttumorsitesinchinesepatients AT zhuxiaoli molecularheterogeneityofsporadiccolorectalcancerwithdifferenttumorsitesinchinesepatients AT caisanjun molecularheterogeneityofsporadiccolorectalcancerwithdifferenttumorsitesinchinesepatients |